Accessibility StatementSkip Navigation BOTHELL, Wash., Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December: The BioLife Solutions Investor Presentation, reflecting the recently refreshed corporate branding, is now available on the Investor Relations section o ...

Core Insights - Five stocks have been added to the Zacks Rank 1 (Strong Buy) List, indicating strong potential for investment Group 1: Company Earnings Estimates - Encore Capital Group, Inc. (ECPG) has seen its earnings estimate increase by 18.5% over the last 60 days [1] - PJT Partners Inc. (PJT) has experienced a 9.6% increase in its earnings estimate over the last 60 days [2] - Everus Construction Group, Inc. (ECG) has had its earnings estimate rise by 11.6% in the past 60 days [3] - United Fire Group, Inc. (UFCS) has seen a significant increase of 29.7% in its earnings estimate over the last 60 days [3] - BioLife Solutions, Inc. (BLFS) has experienced the largest increase, with a 40% rise in its earnings estimate over the last 60 days [4]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Core Insights - The company is focusing on a newly launched strategy aimed at addressing current global challenges, particularly in the context of security and trust issues faced by customers [1][2]. Group 1: Company Strategy - The company has recently updated its strategy, which was launched on Tuesday, and aims to provide deeper insights into its future direction [1]. - The leadership team, including the CEO, CTO, and CFO, is actively involved in communicating this strategy to stakeholders [1]. Group 2: Industry Context - The current global environment is characterized by increasing security issues, warfare, and technical vulnerabilities, which are impacting the industry [2]. - Customers, especially in Europe, are expressing concerns about trust in the face of these challenges, indicating a shift in focus towards security solutions [2].

Core Insights - BioLife Solutions, Inc. (BLFS) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.01 per share, marking a significant earnings surprise of +500.00% [1] - The company achieved revenues of $28.07 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.73%, although this represents a decline from $30.57 million in the same quarter last year [2] - BioLife Solutions has consistently outperformed consensus EPS estimates over the last four quarters, indicating a positive trend in earnings performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $26.48 million, while for the current fiscal year, the estimate is $0.05 on revenues of $101.1 million [7] - The company's earnings outlook will be influenced by management's commentary during the earnings call, which is crucial for assessing future stock performance [3][4] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5][6]

Financial Data and Key Metrics Changes - In Q3 2025, total revenue increased by 31% year-over-year to $28.1 million, driven by a 33% increase in cell processing revenue [4][12] - Adjusted EBITDA margin expanded by 500 basis points year-over-year to 28%, reflecting improved profitability [4][14] - GAAP net income was $621,000 or $0.01 per share, compared to a net loss of $471,000 or $0.01 per share in the prior year [14] Business Line Data and Key Metrics Changes - Cell processing revenue reached $25.4 million, a 33% year-over-year increase, with biopreservation media products representing over 80% of total cell processing revenue [6][12] - The direct versus distributor sales mix shifted to approximately 70/30, indicating a stronger focus on direct sales [7] Market Data and Key Metrics Changes - BioLife's biopreservation media products were embedded in 16 approved therapies and utilized in over 250 relevant commercially sponsored CGT clinical trials in the U.S., representing over a 70% market share [9] - The company is involved in more than 30 phase III trials, where its share is nearly 80%, highlighting its market leadership [9] Company Strategy and Development Direction - The sale of the Evo Cold Chain Logistics product line for approximately $25.5 million allows the company to focus on its core competencies and operational strengths [5] - The company aims to explore inorganic growth opportunities while maintaining a disciplined approach to capital allocation [36][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustainable revenue growth and margin expansion due to the strong performance of commercial customers and late-stage clinical programs [11][54] - The company raised its full-year 2025 revenue guidance to $95-$96 million, reflecting a growth rate of 27%-29% on a like-for-like basis [17] Other Important Information - Cash and marketable securities balance as of September 30, 2025, was approximately $98.4 million, slightly down from $100.2 million as of June 30, 2025 [15] - The company expects adjusted gross margin for the full year to be in the mid-60s, with a reduction in GAAP net loss and expansion in adjusted EBITDA margin compared to 2024 [18] Q&A Session Summary Question: What is the pricing outlook for the upcoming years? - Management anticipates a price increase of 4% to 6% in 2026, with year-to-date pricing growth higher than list price increases due to customer contract negotiations [22][23] Question: What is the status of direct sales headcount? - The company has added one sales representative focused on cross-selling, bringing the total to about six, with plans to potentially add more in 2026 [24][25] Question: How is the company viewing the funding environment for biotech? - Management noted that commercial customers are expected to drive growth, with a robust clinical pipeline supporting this outlook [28][29] Question: Are there any lingering costs from the Evo platform? - There are no lingering operational expenses from the Evo platform, and the Q3 results serve as a good baseline for Q4 [36] Question: What are the capital allocation plans post-Evo sale? - The company is interested in exploring adjacent opportunities that align with its core competencies while being disciplined in its approach to avoid negatively impacting its financial profile [37][38]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was $28.1 million, representing a 31% increase compared to $21.4 million for the same period in 2024[190]. - Product revenue for the three months ended September 30, 2025, was $26.3 million, an increase of $6.3 million, or 32%, compared to the same period in 2024[191]. - Cell processing product revenue increased by $6.3 million, or 33%, during the three months ended September 30, 2025, driven by increased customer demand for commercially approved therapies[192]. - Rental revenue for the three months ended September 30, 2025, was $1.8 million, representing a 24% increase compared to $1.4 million for the same period in 2024[197]. - Total revenue for the nine months ended September 30, 2025, was $77.4 million, a 30% increase from $59.5 million for the same period in 2024[190]. - Product revenue from cell processing products increased by $16.6 million, or 31%, during the nine months ended September 30, 2025, compared to the same period in 2024[193]. - Product revenue from evo and Thaw products increased by $0.9 million, or 54%, during the nine months ended September 30, 2025, compared to the same period in 2024[195]. - Service revenues were immaterial during the three and nine months ended September 30, 2025, and 2024[196]. Operating Expenses - Total operating expenses increased by $6.3 million, or 29%, for the three months ended September 30, 2025, and by $30.8 million, or 48%, for the nine months ended September 30, 2025 compared to the same periods in 2024[199]. - Cost of product, rental, and service revenue rose by $2.7 million, or 37%, for the three months ended September 30, 2025, and by $7.2 million, or 36%, for the nine months ended September 30, 2025 compared to the same periods in 2024[200]. - General and administrative expenses increased by $2.7 million, or 29%, for the three months ended September 30, 2025, and by $5.9 million, or 20%, for the nine months ended September 30, 2025 compared to the same periods in 2024[204][205]. - Research and development expenses increased by $0.8 million, or 43%, for the three months ended September 30, 2025, and by $1.6 million, or 27%, for the nine months ended September 30, 2025 compared to the same periods in 2024[209][210]. Financial Position - The company had $98.4 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2025, down from $109.2 million at the end of 2024[216]. - The company believes its current level of cash and liquid assets will be sufficient to meet liquidity needs for at least the next twelve months[223]. - Net cash provided by operating activities increased to $15.2 million for the nine months ended September 30, 2025, up from $6.8 million in the same period of 2024, reflecting stronger revenues and improved working capital management[225]. - Net cash used in investing activities rose to $72.7 million for the nine months ended September 30, 2025, compared to $15.3 million in 2024, primarily due to $61.4 million in additional purchases of marketable securities[226]. - The company invested $10.2 million in the acquisition of PanTHERA during the nine months ended September 30, 2025, which was $2.8 million less than the cash used for the divestiture of Global Cooling in Q2 2024[227]. - Net cash used in financing activities totaled $8.4 million for the nine months ended September 30, 2025, compared to $2.7 million in 2024, driven by a $7.5 million increase in Term Loan payments[228]. - As of September 30, 2025, the company's total short-term purchase obligations amounted to $7.4 million[230]. - The company does not use derivative financial instruments in its investment portfolio, and fluctuations in interest rates have not materially impacted its consolidated financial statements[234]. Strategic Actions - The divestiture of SAVSU was completed on October 6, 2025, and is presented as part of continuing operations as of September 30, 2025[181]. - The company continues to evaluate opportunities for organic growth innovations, partnerships, and acquisitions to maximize the value of its product platforms[180]. - The company entered into the SAVSU Purchase Agreement for an aggregate purchase price of $25.5 million on October 6, 2025[217]. - The PanTHERA Transaction was completed on April 4, 2025, with an aggregate purchase price of $16.8 million, including $11.5 million in cash[218]. - The company received net proceeds of $71.3 million from the SciSafe Divestiture on November 12, 2024[221]. Interest Income - Interest income increased by $0.7 million, or 321%, for the three months ended September 30, 2025, and by $2.6 million, or 369%, for the nine months ended September 30, 2025 compared to the same periods in 2024[213][215].

Revenue and Growth - Cell Processing revenue for Q3 2025 was $25.4 million, up 33% from Q3 2024[1] - Total revenue for Q3 2025 was $28.1 million, an increase of 31% from $21.4 million in Q3 2024[12] - The company raised its 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million, reflecting year-over-year growth of 26% to 28%[25] - The company expects total 2025 revenue guidance of $95.0 million to $96.0 million, representing a 27% - 29% increase compared to 2024[21] - Product revenue for Q3 2025 was $26,250,000, a 31.6% increase from $19,928,000 in Q3 2024[37] - Total revenue for the nine months ended September 30, 2025, reached $77,429,000, up 30% from $59,539,000 in the same period of 2024[42] - Total revenues for the nine months ended September 30, 2025, reached $71,449,000, compared to $64,000,000 for the same period in 2024, reflecting a growth of approximately 11%[53] Profitability and Margins - Adjusted EBITDA for Q3 2025 was $7.8 million, or 28% of revenue, compared to $5.0 million, or 23% of revenue, in Q3 2024[24] - Gross margin (GAAP) for Q3 2025 was 62%, down from 63% in Q3 2024, while adjusted gross margin was 64%, down from 67%[18] - Gross profit for Q3 2025 was $17,325,000, representing a gross margin of 62%, compared to 63% in Q3 2024[42] - Adjusted operating income for Q3 2025 was $1,293,000, compared to $167,000 in Q3 2024[46] - Adjusted EBITDA for the three months ended September 30, 2025, was $7,832,000, representing 28% of revenue, compared to $5,021,000 or 23% of revenue in the same quarter of 2024[50] - Adjusted gross margin for the three months ended September 30, 2025, was 66%, compared to 67% in the same period of 2024[56] Net Income and Losses - Net income (GAAP) for Q3 2025 was $0.6 million, compared to a net loss of $0.5 million in Q3 2024[18] - Net income for Q3 2025 was $621,000, a significant improvement from a net loss of $1,703,000 in Q3 2024[38] - For the three months ended September 30, 2025, BioLife Solutions reported a net income of $621,000 compared to a net loss of $471,000 for the same period in 2024[47] - Adjusted net income for the three months ended September 30, 2025, was $2,044,000, significantly up from $34,000 in the prior year[47] - Operating loss for the nine months ended September 30, 2025, was $17,949,000, compared to a loss of $5,019,000 in the same period of 2024[46] - Operating loss for the nine months ended September 30, 2025, was $(16,917,000), compared to $(4,481,000) for the same period in 2024[53] Cash and Assets - Cash, cash equivalents, and marketable securities as of September 30, 2025, were $98.4 million[24] - Cash and cash equivalents at the end of Q3 2025 were $29,481,000, down from $24,161,000 at the end of Q3 2024[41] - Total assets as of September 30, 2025, were $392,081,000, slightly down from $399,487,000 at the end of 2024[40] - The company reported a net cash provided by operating activities of $15,199,000 for the nine months ended September 30, 2025, compared to $6,786,000 in 2024[41] Expenses and Costs - The company incurred $15,521,000 in IPR&D expenses during the nine months ended September 30, 2025, primarily related to the PanTHERA acquisition[50] - The company reported a significant increase in share-based compensation, totaling $15,897,000 for the nine months ended September 30, 2025, compared to $12,233,000 in the prior year[50] - The company incurred acquisition and divestiture costs of $1,245,000 for FY2024, with YTD 2025 costs amounting to $1,309,000[60][61] - Depreciation expenses for FY2024 totaled $643,000, while YTD 2025 expenses reached $588,000[60][61] - Interest expense for FY2024 was $766,000, with interest income for YTD 2025 reported at $(1,875,000)[60][61] Divestitures and Acquisitions - The divestiture of the evo cold chain logistics business was completed for $25.5 million in cash[7] - The company anticipates the divestiture of evo to qualify as Discontinued Operations in the Annual Report for the year ended December 31, 2025[51] Accumulated Deficit - The accumulated deficit increased to $(350,766,000) as of September 30, 2025, from $(335,101,000) at the end of 2024[40] Other Financial Metrics - For FY2024, the company reported a total loss from continuing operations of $8,789,000, with Q3 showing a slight income of $300,000[60] - Adjusted EBITDA from continuing operations for FY2024 was $13,337,000, representing 18% of revenue[60] - In Q1 2025, the company experienced a loss from continuing operations of $14,634,000, with Q2 showing a significant loss of $15,454,000[61] - Adjusted EBITDA from continuing operations for YTD 2025 reached $17,722,000, which is 25% of revenue[61] - Share-based compensation (non-cash) totaled $15,282,000 for FY2024, with Q1 2025 reporting $15,468,000[60][61] - The company recorded an inventory reserve cost of $247,000 in Q4 2024[60]

Core Insights - BioLife Solutions, Inc. will release its third quarter 2025 financial results on November 6, 2025, after market close [1] - A conference call and live webcast will be held on the same day at 4:30 PM ET to discuss the financial results and provide a business update [1] Company Overview - BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market [3] - The company specializes in solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution [3]

Core Insights - BioLife Solutions, Inc. has announced the sale of its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC, for $25.5 million in cash to Peli BioThermal, enhancing its focus on high-margin recurring revenue [1][2]. Company Overview - BioLife Solutions is a leading developer and supplier of cell processing tools and services for the cell and gene therapy market, facilitating the commercialization of new therapies by providing solutions that maintain the health and function of biologic materials during various stages [2].